Enhertu (trastuzumab deruxtecan)

pCPA File Number: 22410

Negotiation Status:

Concluded with an LOI

Indication(s):

Indicated as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CADTH Project Number:

PC0305

pCPA Engagement Letter Issued:

2023-09-20

Negotiation Process Concluded:

2024-02-02